Abstract
The aim of this preclinical study was to investigate whether the monoclonal antibody OV-TL 3 might be useful for targeting ovarian cancer. Immunocytochemical studies on frozen sections showed intensive staining in > 90% (62/67) of primary as well as metastasized ovarian carcinomas. Slight cross-reactivity was observed with endocervical, oviductal epithelium as well as with lymphoid cells. Using immunoelectron microscopy the antibody stained a tumour cell surface antigen (OA3). No cross reactivity with the antibodies OC125 or MOv18 were found in inhibition studies on NIH:OVCAR:3 cells. The antigen could be quantified in tumour extracts or cyst fluids, but could not be traced in patient serum using a sandwich radio-immuno assay. The affinity constant was 1.4 x 10-9 M-1 as determined by Satchard analysis and displacement studies. Biodistribution studies with 125-I-labeled OV-TL 3 in athymic mice showed that tumour uptake with OV-TL 3 was significant higher than with OC125, and almost 7 times higher than with a non-specific control antibody (OV-TL 19). Radioiodinated F(ab’)2 fragments revealed a much faster clearance, a lower tumour uptake (ID%/g) but much better tumour/tissue ratios from 6.9 to 53. The attachment of OV-TL 3 to tumour cells and subsequent internalisation were studied with confocal laser scanning microscopy. Internalisation of the antibody was noticed upon long term incubation (>3 hours) in a considerable number of OVCAR:3 cells. The results suggest that OV-TL 3 might be a potent antibody for targeting label or immunotoxins to ovarian cancer cells.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Campos Cardoso A. (1987) A cancer morbidity and mortality 1984–1985. Maandber Gezondheid (CBS) 6, 5–25.
Bast R. Jr, Feeney M., Lazarus H., Nadler L., Colvin R., Knapp R. (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest 68, 1331–1337.
Boerman O., Niekerk C. van, Makkink K., Hanselaar A., Kenemans P., Poels L. (1990b) A comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. Int. J. Gynecol. Pathol. (in press).
Boerman O., Makkink W., Thomas C., Hanselaar A., Yedema C., Kenemans P., Poels L. (1990a) Monoclonal antibodies that discriminate between human ovarian carcinomas and benign ovarian tumours. Europ. J. Cancer Clin. Oncol. (in press).
Boerman O., Massuger L., Makkink W., Thomas C., Kenemans P., Poels L. (1990c) Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies. in: Development and application of monoclonal antibodies against ovarian cancer, pp 73–82. Thesis 1990 by O.C. Boerman, University of Nijmegen, The Netherlands.
Boerman O., Makkink W., Massuger L., Thomas C., Kenemans P., Hanselaar A., Poels L. (1989) Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids. Anticancer Res. 9, 551–558.
Epenetos A., Lavender J., Kenemans P., Poels L. (1987) Early results of the monoclonal antibody OV-TL 3 in specific detection of ovarian cancer. J. Clin Oncol 5, 160–161.
Fraker P., Speck J. (1978) Protein and cell membrane iodination with a sparingly soluble chloramide 1,3,4,6- tetrachloro3∝,6∝diphenylglucoril. Biochem Biophys. Res. Commun. 80, 849–857.
Hamilton T., Young R., Mc Koy W., Grotzinger K., Green J., Chu E., Whang-Peng J., Rogan A., Ozols R. (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR:3) with androgen and estrogen receptors. Cancer Res. 43, 5379–5383.
Hnatowich D., Childs RL, Lanteigne D., Najafi A. (1983) The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method. J. Immunol. Method. 65, 147–157.
Köhler G., Milstein C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497.
Massuger L., Boerman O., Kenemans P., Verheijen R., Claessens R., Poels L., Broek W. van den, Corstens F. Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab’)2 fragments in tumor-bearing athymic mice. (1990) in: Development and application of monoclonal antibodies against ovarian cancer, pp 83–96. Thesis 1990 by O.C. Boerman, University of Nijmegen, The Netherlands.
Miotti S., Canevari S., Ménard S., Mezzanzanica D, Porro G., Pupa S., Reggazoni M., Tagliabue E., Colnaghi M. (1987) Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer 39, 297–303.
Mosely K., Battaille A., Knapp R., Haisma H. (1988) Localization of radiolabeled F(ab’)2 fragment of monoclonal antibodies in nude mice bearing intraperitonelally growing human ovarian xenografts. Int. J. Cancer 42, 368–372.
Neyt J., Burg, M. van der, Vriesendorp R., Lindert A. van, Lent M. van, Bokkel Huinink W. ten, Oosterom A. van, Kooyman C., Harmelynck J., Houweling J. van, Pinedo H. (1984) Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet ii, 594–600.
Niekerk C. van, Poels L., Jap P., Smeets D., Thomas C., Ramaekers F., Vooijs G. (1988) Characterization of a human ovarian carcinoma cell line OTN 14 derived from a mucinous cystadenocarcinoma. Int. J.Cancer 42, 104–111.
Niekerk C. van, Jap P., Thomas C., Smeets D., Ramaekers F., Poels L. (1989) Marker profile of mesothelial cells versus ovarian carcinoma cells. Int. J. Cancer 43, 1065–1071.
Poels L., Peters D., Megen Y. van, Vooijs G., Verheijen R., Willemen A., Niekerk C. van, Jap P., Mungyer G., Kenemans P. (1986) Monoclonal antibody against ovarian tumour-associated antigens. J. Natl. Cancer Inst. 76, 781–791.
Ramaekers F., Niekerk C. van, Poels L., Schaafsma E., Huysmans A., Robben H., Schaart H., Vooijs P. (1990) Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. Am. J. Pathol. (in press).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Poels, L.G. et al. (1990). Biodistribution, Binding and Internalisation of Monoclonal Antibodies to Human Ovarian Carcinoma Cells. In: Crommelin, D.J.A., Schellekens, H. (eds) From Clone to Clinic. Developments in Biotherapy, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-3780-5_9
Download citation
DOI: https://doi.org/10.1007/978-94-011-3780-5_9
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5683-0
Online ISBN: 978-94-011-3780-5
eBook Packages: Springer Book Archive